Literature DB >> 25273091

TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer.

Chaya Levovitz1, Dan Chen2, Emma Ivansson2, Ulf Gyllensten2, John P Finnigan3, Sara Alshawish3, Weijia Zhang4, Eric E Schadt5, Marshal R Posner6, Eric M Genden7, Paolo Boffetta8, Andrew G Sikora9.   

Abstract

Only a minority of those exposed to human papillomavirus (HPV) develop HPV-related cervical and oropharyngeal cancer. Because host immunity affects infection and progression to cancer, we tested the hypothesis that genetic variation in immune-related genes is a determinant of susceptibility to oropharyngeal cancer and other HPV-associated cancers by performing a multitier integrative computational analysis with oropharyngeal cancer data from a head and neck cancer genome-wide association study (GWAS). Independent analyses, including single-gene, gene-interconnectivity, protein-protein interaction, gene expression, and pathway analysis, identified immune genes and pathways significantly associated with oropharyngeal cancer. TGFβR1, which intersected all tiers of analysis and thus selected for validation, replicated significantly in the head and neck cancer GWAS limited to HPV-seropositive cases and an independent cervical cancer GWAS. The TGFβR1 containing p38-MAPK pathway was significantly associated with oropharyngeal cancer and cervical cancer, and TGFβR1 was overexpressed in oropharyngeal cancer, cervical cancer, and HPV(+) head and neck cancer tumors. These concordant analyses implicate TGFβR1 signaling as a process dysregulated across HPV-related cancers. This study demonstrates that genetic variation in immune-related genes is associated with susceptibility to oropharyngeal cancer and implicates TGFβR1/TGFβ signaling in the development of both oropharyngeal cancer and cervical cancer. Better understanding of the immunogenetic basis of susceptibility to HPV-associated cancers may provide insight into host/virus interactions and immune processes dysregulated in the minority of HPV-exposed individuals who progress to cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25273091      PMCID: PMC4496416          DOI: 10.1158/0008-5472.CAN-14-0602-T

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

1.  Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer.

Authors:  Xiaoxiang Guan; Erich M Sturgis; Dapeng Lei; Zhensheng Liu; Kristina R Dahlstrom; Qingyi Wei; Guojun Li
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells.

Authors:  Weiguo Cui; Ying Liu; Jason S Weinstein; Joseph Craft; Susan M Kaech
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

3.  Mycobacterium bovis BCG and purified protein derivative-induced reduction in the CD80 expression and the antigen up-take function of dendritic cells from patients with cervical cancer.

Authors:  Alagar Manickam; Muthukumaran Sivanandham
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-08-06       Impact factor: 2.435

4.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

Review 5.  Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy.

Authors:  A S Ihloff; C Petersen; M Hoffmann; R Knecht; S Tribius
Journal:  Oral Oncol       Date:  2010-09-16       Impact factor: 5.337

6.  GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Russell S Taichman
Journal:  Exp Hematol       Date:  2009-11-14       Impact factor: 3.084

7.  Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.

Authors:  Elaine M Smith; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Eva Hamsikova; Lubomir P Turek
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

8.  Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway.

Authors:  Deborah French; Francesca Belleudi; Maria Vittoria Mauro; Francesca Mazzetta; Salvatore Raffa; Vincenza Fabiano; Antonio Frega; Maria Rosaria Torrisi
Journal:  Mol Cancer       Date:  2013-05-07       Impact factor: 27.401

9.  Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma.

Authors:  G Halec; D Holzinger; M Schmitt; C Flechtenmacher; G Dyckhoff; B Lloveras; D Höfler; F X Bosch; M Pawlita
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

Review 10.  The advantages and limitations of trait analysis with GWAS: a review.

Authors:  Arthur Korte; Ashley Farlow
Journal:  Plant Methods       Date:  2013-07-22       Impact factor: 4.993

View more
  23 in total

Review 1.  Emerging roles of microRNAs and their implications in uveal melanoma.

Authors:  Chun Yang; Yuejiao Wang; Pierre Hardy
Journal:  Cell Mol Life Sci       Date:  2020-08-11       Impact factor: 9.261

2.  Inherited alterations of TGF beta signaling components in Appalachian cervical cancers.

Authors:  Thomas J Knobloch; Juan Peng; Erinn M Hade; David E Cohn; Mack T Ruffin; Michael A Schiano; Byron C Calhoun; William C McBee; Jamie L Lesnock; Holly H Gallion; Jondavid Pollock; Bo Lu; Steve Oghumu; Zhaoxia Zhang; Marta T Sears; Blessing E Ogbemudia; Joseph T Perrault; Logan C Weghorst; Erin Strawser; Cecilia R DeGraffinreid; Electra D Paskett; Christopher M Weghorst
Journal:  Cancer Causes Control       Date:  2019-08-21       Impact factor: 2.506

Review 3.  Immunotherapy for HPV Malignancies.

Authors:  Maxwell Y Lee; Clint T Allen
Journal:  Semin Radiat Oncol       Date:  2021-10       Impact factor: 5.421

4.  Increased Abundances of CD16+ Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4+ T Cell Disturbances in Oropharyngeal Cancer.

Authors:  Christian Idel; Christina Polasky; Julika Ribbat-Idel; Kristin Loyal; Sven Perner; Dirk Rades; Karl-Ludwig Bruchhage; Ralph Pries
Journal:  Biomedicines       Date:  2022-06-09

Review 5.  Exploiting Canonical TGFβ Signaling in Cancer Treatment.

Authors:  Qi Liu; Genwen Chen; Jade Moore; Ines Guix; Dimitris Placantonakis; Mary Helen Barcellos-Hoff
Journal:  Mol Cancer Ther       Date:  2021-10-20       Impact factor: 6.009

Review 6.  Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.

Authors:  Sofia R Gameiro; Julius Strauss; James L Gulley; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

Review 7.  Biomarkers in anal cancer: from biological understanding to stratified treatment.

Authors:  Christopher M Jones; Vicky Goh; David Sebag-Montefiore; Duncan C Gilbert
Journal:  Br J Cancer       Date:  2016-12-06       Impact factor: 7.640

Review 8.  Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer.

Authors:  Ryan M Carr; Zhaohui Jin; Joleen Hubbard
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

9.  PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Lin-Lin Bu; Cong-Fa Huang; Wen-Feng Zhang; Wan-Jun Chen; J Silvio Gutkind; Ashok B Kulkarni; Zhi-Jun Sun
Journal:  Oncotarget       Date:  2015-12-08

10.  In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.

Authors:  Peter A van Dam; Pieter-Jan H H van Dam; Christian Rolfo; Marco Giallombardo; Christophe van Berckelaer; Xuan Bich Trinh; Sevilay Altintas; Manon Huizing; Kostas Papadimitriou; Wiebren A A Tjalma; Steven van Laere
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.